Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02922907 · ClinicalTrials.gov registry record · NA

Rice Bran Supplementation in Treated HIV Infection

A NA study, sponsored by University of Southern California.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT02922907: Completed NA study, sponsored by University of Southern California.

NCT02922907 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02922907, a NA study, has completed, sponsored by University of Southern California.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

Double-blind placebo-controlled randomized trial of Arabinoxylan Rice Bran Supplementation for 12 weeks with BRM4 in HIV-infected participants with inadequate immune reconstitution.

Primary Outcome

Marker of macrophage activation

Interventions

  • DIETARY_SUPPLEMENT arabinoxylan rice bran
  • DIETARY_SUPPLEMENT Placebo for arabinoxylan rice bran

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2017-03-24
Est. Completion 2019-12-03
Phase NA
University of Southern California

617 total trials

What the finished NCT02922907 record still lists

NCT02922907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which arabinoxylan rice bran is the first listed.

NCT02922907 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02922907 about?

NCT02922907 is a clinical study titled "Rice Bran Supplementation in Treated HIV Infection". Double-blind placebo-controlled randomized trial of Arabinoxylan Rice Bran Supplementation for 12 weeks with BRM4 in HIV-infected participants with inadequate immune reconstitution.

What is the current status of trial NCT02922907?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2017-03-24. Estimated completion is 2019-12-03.

What interventions are being tested in trial NCT02922907?

The interventions under investigation include: arabinoxylan rice bran (DIETARY_SUPPLEMENT), Placebo for arabinoxylan rice bran (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02922907?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02922907's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02922907, the US trial registry maintained by the National Library of Medicine. NCT02922907 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.